Assessing CSL (ASX:CSL) Valuation After Interim CEO Review And Financial Update

Simply Wall St.05-16 11:54

AdvertisementInterim CEO review and financial update draw investor focus CSL (ASX:CSL) has attracted fresh attention after a recent shareholder and analyst call covering the Interim CEO’s review of ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635705295?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","is_english":true,"pubTime":"2026-05-16 11:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635705295","market":"nz","top_or_hot":-1,"title":"Assessing CSL (ASX:CSL) Valuation After Interim CEO Review And Financial Update","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementInterim CEO review and financial update draw investor focus CSL (ASX:CSL) has attracted fresh attention after a recent shareholder and analyst call covering the Interim CEO’s review of ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/assessing-csl-asxcsl-valuation-after-interim-ceo-review-and\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing CSL (ASX:CSL) Valuation After Interim CEO Review And Financial Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing CSL (ASX:CSL) Valuation After Interim CEO Review And Financial Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-16 11:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/assessing-csl-asxcsl-valuation-after-interim-ceo-review-and><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementInterim CEO review and financial update draw investor focus CSL (ASX:CSL) has attracted fresh attention after a recent shareholder and analyst call covering the Interim CEO’s review of ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/assessing-csl-asxcsl-valuation-after-interim-ceo-review-and\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7511","symbol_name":"ESG概念","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/assessing-csl-asxcsl-valuation-after-interim-ceo-review-and","article_id":"2635705295","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/assessing-csl-asxcsl-valuation-after-interim-ceo-review-and","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2635705295","pubTimestamp":1778903640,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Interim CEO review and financial update draw investor focus\nCSL (ASX:CSL) has attracted fresh attention after a recent shareholder and analyst call covering the Interim CEO’s review of the past 3 months and a financial update, prompting investors to reassess the stock’s current setup.\nSee our latest analysis for CSL.\nCSL’s share price has fallen 43.03% year to date and the 1 year total shareholder return is down 58.49%. The recent call therefore comes after a sustained loss of momentum, with...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7511":"ESG概念","BK7508":"医药生物股","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","BK7501":"新冠治疗股","BK7067":"生物科技","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4086":"建筑产品","CSL.AU":"CSL LIMITED","CSL":"卡莱尔伙伴"},"translate_title":"在中期首席执行官审查和财务更新后评估CSL(ASX：CSL)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"CSL":1.5,"CSL.AU":1.5},"content_text":"AdvertisementInterim CEO review and financial update draw investor focus CSL (ASX:CSL) has attracted fresh attention after a recent shareholder and analyst call covering the Interim CEO’s review of the past 3 months and a financial update, prompting investors to reassess the stock’s current setup. See our latest analysis for CSL. CSL’s share price has fallen 43.03% year to date and the 1 year total shareholder return is down 58.49%. The recent call therefore comes after a sustained loss of momentum, with the A$97.96 price reflecting investors reassessing growth prospects and risks. If this kind of reset has you reconsidering where you look for opportunities, it could be a good time to scan other health focused names through our healthcare and AI stock ideas via 9 healthcare AI stocks After a share price slide and a current A$97.96 level, plus a reported intrinsic discount of 47.39%, the key question is whether CSL is now undervalued or if the market is already pricing in its future growth. Most Popular Narrative: 62.8% Undervalued According to Ramsee’s widely followed narrative, CSL’s fair value is estimated at A$263.33 per share, compared with the current A$97.96 share price.  The fair value of CSL is estimated using a Discounted Cash Flow (DCF) approach, which values the company based on the present value of its expected future free cash flows. This methodology is described as appropriate for a company like CSL with a strong market position and relatively predictable long-term cash flow generation potential.  Read the complete narrative. Want to see what has to happen in CSL Behring, Seqirus and Vifor for this valuation to stack up? The narrative focuses on earnings recovery, margin rebuild and disciplined reinvestment. Result: Fair Value of A$263.33 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, investors still need to watch for risks such as potential changes in US trade or tariffs and any setbacks in CSL Behring’s margin recovery, which could challenge this undervalued case. Find out about the key risks to this CSL narrative. Next Steps With both risks and rewards in the mix, how does CSL really stack up for you as an investor today? Move quickly, review the full picture for yourself, and weigh the 2 key rewards and 4 important warning signs Looking for more investment ideas? If CSL is on your radar, do not stop there. A few minutes with the right tools can surface opportunities you might regret missing later.  Spot potential bargains early by scanning companies that currently screen as 9 high quality undervalued stocks Prioritise resilience by focusing on businesses highlighted in the 6 resilient stocks with low risk scores Hunt for future standouts through the screener containing 13 high quality undiscovered gems   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635705295","isCrawlerRequest":true}